TARGETED treatments for prostate cancer were a central theme at the European Society for Medical Oncology (ESMO) Congress ...

The firm's Phase I/II study yielded responses in mCRPC patients with androgen receptor mutations but it wasn't as promising in HR-positive breast cancer.

Pre-biopsy MRIs can help doctors diagnose and treat prostate cancer more accurately. Here’s when you should get one.

SAN FRANCISCO — A genomic test can identify patients with recurrent prostate cancer who are most likely to benefit from adding hormone therapy to secondary radiotherapy, according to findings ...

Please provide your email address to receive an email when new articles are posted on . A genetic test that identifies the PAM50 biomarker predicted which patients with recurrent prostate cancer would ...